—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Tubize-Fin (TUB.BR) — the peer cohort

As of 2026-11-05 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Tubize-Fin ranks 7 of 7 in its cohort on the Closelooknet composite (31/100) — the cohort is led by Halozyme Therapeutics Inc at 72/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
TUB.BR Tubize-Fin 31 67 20 22 info 3.9%
HALO Halozyme Therapeutics Inc 72 93 94 37 ok 8.2%
ONC BeOne Medicines AG 65 88 64 29 ok 4.4%
ARGX.BR Argen-X 64 77 75 29 info 11.8%
UCB.BR UCB SA 64 72 70 44 info 0.7%
ARGX argenx NV ADR 63 71 74 28 info 16.6%
RIGL Rigel Pharmaceuticals Inc 63 97 90 72 info 13.1%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-11-05

Quick answers

Who are Tubize-Fin's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Halozyme Therapeutics Inc (HALO), BeOne Medicines AG (ONC), Argen-X (ARGX.BR), UCB SA (UCB.BR), argenx NV ADR (ARGX), Rigel Pharmaceuticals Inc (RIGL), as of 2026-11-05.

How does TUB.BR score against its peers?

Tubize-Fin's composite reads 31/100, ranking 7 of 7 in its cohort as of 2026-11-05; the cohort's highest composite is Halozyme Therapeutics Inc at 72/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.